The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: The objective of this study was to assess the risk of acute pancreatitis in patients with type 2 diabetes compared with that in patients without diabetes. We also examined the risk of biliary disease (defined as occurrence of cholelithiasis, acute cholecystitis, or cholecystectomy), which is a major cause of pancreatitis. RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort study using a large, geographically diverse U.S. health care claims database. Eligible patients (≥18 years) were enrolled for at least 12 continuous months (1999–2005), with no incident events of pancreatitis or biliary disease during that 1 year baseline period. ICD-9 codes and prescription data were used to identify patients with type 2 diabetes; ICD-9 codes were also used to identify cases of pancreatitis and biliary disease. Overall, 337,067 patients with type 2 diabetes were matched on age and sex with 337,067 patients without diabetes. Incidence rates of disease and 95% CI were calculated per 100,000 person-years of exposure. RESULTS: The type 2 diabetic cohort had a 2.83-fold (95% CI 2.61–3.06) greater risk of pancreatitis and 1.91-fold (1.84–1.99) greater risk of biliary disease compared with the nondiabetic cohort. Relative to patients of corresponding age without diabetes, younger type 2 diabetic patients had the highest risk of pancreatitis (<45 years: incidence rate ratio [IRR] 5.26 [95% CI 4.31–6.42]; ≥45 years: 2.44 [2.23–2.66]). CONCLUSIONS: These data suggest that patients with type 2 diabetes may have an increased risk of acute pancreatitis and biliary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of Overweight on the Risk of Developing Common Chronic Diseases During a 10-Year Period
Field, A. E., Coakley, E. H., Must, A., Spadano, J. L., Laird, N., Dietz, W. H., Rimm, E., & Colditz, G. A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1581 · Cited by 1,694
Steinberg, W., & Tenner, S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301706 · Cited by 757
Whitcomb, D. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp054958 · Cited by 745
Trends in the Epidemiology of the First Attack of Acute Pancreatitis: A Systematic Review
Yadav, D., & Lowenfels, A. B. (2006) · Pancreas · doi:10.1097/01.mpa.0000236733.31617.52 · Cited by 663
Risk of symptomatic gallstones in women with severe obesity
Stampfer, M., Maclure, K., Colditz, G., Manson, J., & Willett, W. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.3.652 · Cited by 363
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Obesity: A Risk Factor for Severe Acute Biliary and Alcoholic Pancreatitis
Suazo-Barahona, J., Carmona-Sánchez, R., Robles‐Díaz, G., Milke-García, P., Vargas-Vorácková, F., Uscanga-Domínguez, L. F., & Peláez‐Luna, M. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.442_l.x · Cited by 120
Torgerson, J., Lindroos, A. K., Näslund, I., & Peltonen, M. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07429.x · Cited by 117
Shetty, S., Secnik, K., & Oglesby, A. K. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.7.559 · Cited by 112
Gallstone disease and related risk factors in a large cohort of diabetic patients
Pagliarulo, M., Fornari, F., Fraquelli, M., Zoli, M., Giangregorio, F., Grigolon, A., Peracchi, M., & Conte, D. (2003) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.10.007 · Cited by 107
Research works printed but not linked: 4
- Kingsnorth, 2006, Acute pancreatitis, Br Med J, 332, 1072, 10.1136/bmj.332.7549.1072 · doi:10.1136/bmj.332.7549.1072
- Olokoba, 2007, Gallstone disease and type-2 diabetes mellitus—the link, J Coll Surgeons Pak, 17, 594
- Harley, 2005, Anticoagulation therapy in patients with chronic atrial fibrillation: a retrospective claims data analysis, Curr Med Res Opin, 21, 215, 10.1185/030079904X20321 · doi:10.1185/030079904x20321
- Rothman, 1998, Modern Epidemiology
Cited by
The Epidemiology of Pancreatitis and Pancreatic Cancer
Yadav, D., & Lowenfels, A. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.068 · Cited by 1,974
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Lankisch, P. G., Apte, M., & Banks, P. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60649-8 · Cited by 1,147
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Issues in Hypertriglyceridemic Pancreatitis: An Update
Scherer, J., Singh, V. P., Pitchumoni, C. S., & Yadav, D. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436438.60145.5a · Cited by 475
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275
Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Diabetes mellitus secondary to pancreatic diseases (type 3c)—are we neglecting an important disease?
Ewald, N., & Bretzel, R. G. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.12.017 · Cited by 235
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Cao, C., Yang, S., & Zhou, Z. (2020) · Endocrine · doi:10.1007/s12020-020-02223-6 · Cited by 124
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
Lindkvist, B., Appelros, S., Regnér, S., & Manjer, J. (2012) · Pancreatology · doi:10.1016/j.pan.2012.05.002 · Cited by 109
Lando, H. M., Alattar, M., & Dua, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11290.or · Cited by 102
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Thomsen, R. W., Pedersen, L., Møller, N., Kahlert, J., Beck-Nielsen, H., & Sørensen, H. T. (2015) · Diabetes Care · doi:10.2337/dc13-2983 · Cited by 89
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0544-0 · Cited by 70
Nauck, M. A., Muus Ghorbani, M. L., Kreiner, E., Saevereid, H. A., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2019) · Diabetes Care · doi:10.2337/dc19-0415 · Cited by 69
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
No evidence of drug‐induced pancreatitis in rats treated with exenatide for 13 weeks
Tatarkiewicz, K., Belanger, P., Gu, G., Parkes, D., & Roy, D. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12040 · Cited by 56
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
Liraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
Peterson, G. E., & Pollom, R. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02498.x · Cited by 55
Jensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Pancreatitis: A Potential Complication of Liraglutide?
Franks, A. S., Lee, P. H., & George, C. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q789 · Cited by 34
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17
Metadata
- Authors
- Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-02-10
- Volume
- 32
- Issue
- 5
- Pages
- 834-838
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2057913111
- Cited by
- 435
- References
- 13
- FWCI
- 48.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.